Prevalence and importance of coronary microvascular dysfunction in patients with heart failure and reduced or mildly reduced ejection fraction
CMD was present in 66% of patients with chronic heart failure and HFrEF or HFmrEF. Markers of more severe heart failure, including reduced GLS and higher NTproBNP and hsTroponin-T, were independently associated with lower CFR. Reduced right ventricular GLS and higher levels of the biomarkers were also independently associated with CMD.
Authors
- Clara Hjalmarsson (ORCID: https://orcid.org/0000-0002-2395-8989)
- Fredrik Wolfhagen Sand
- Akash Gupta (ORCID: https://orcid.org/0000-0001-9557-8726)
- Erik Michaëlsson (ORCID: https://orcid.org/0000-0001-8643-2821)
- Charlotta Ljungman (ORCID: https://orcid.org/0000-0002-2785-1919)
- Entela Bollano (ORCID: https://orcid.org/0000-0003-3341-2434)
- Carlo Pirazzi (ORCID: https://orcid.org/0009-0003-1572-3789)
- Maria Lagerström‐Fermér (ORCID: https://orcid.org/0000-0001-6632-3767)
- Sara Svedlund (ORCID: https://orcid.org/0000-0002-4359-7463)
- Alastair J. Moss (ORCID: https://orcid.org/0000-0003-4123-2070)
- Lars H. Lund (ORCID: https://orcid.org/0000-0003-1411-4482)
- Charlotte Nordberg Backelin (ORCID: https://orcid.org/0009-0009-2135-2578)
- Camilla Hage (ORCID: https://orcid.org/0000-0002-4142-2416)
- Thomas Brodin (ORCID: https://orcid.org/0000-0002-0696-0294)
- Karl Johan Dahllöf
- Ida Silfversparre
Institutions
- AstraZeneca (United Kingdom) (GB)
- Karolinska University Hospital (SE)
- Sahlgrenska University Hospital (SE)
- Karolinska Institutet (SE)
- AstraZeneca (Netherlands) (NL)
- AstraZeneca (Singapore) (SG)
- AstraZeneca (India) (IN)
- AstraZeneca (Finland) (FI)
- AstraZeneca (Italy) (IT)
- University of Gothenburg (SE)
Publication Details
- Journal
- Open Heart
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1136/openhrt-2025-003509
- Citations
- 1
- Primary Topic
- Cardiovascular Function and Risk Factors
- Type
- article
- Field-Weighted Citation Impact
- 1.39